LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

94.02 -1.67

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

93.45

Máximo

94.38

Métricas clave
By Trading Economics
Ingresos	5.4M -48M
Ventas	6M 57M
Margen de beneficios	-82.974
Empleados	414
EBITDA	5.1M -43M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+41.97% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-565M 5.9B
Apertura anterior	95.69
Cierre anterior	94.02

Noticias sobre sentimiento de mercado

By Acuity

95%

1 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

60 / 65.58 Soporte y Resistencia

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 may 2026, 23:55 UTC

Ganancias

Review & Preview: Still Going Strong -- Barrons.com

8 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 may 2026, 20:49 UTC

Ganancias

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 may 2026, 20:25 UTC

Ganancias

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 may 2026, 19:43 UTC

Ganancias

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 may 2026, 19:43 UTC

Ganancias

Cencosud 1Q Net $115M

8 may 2026, 19:20 UTC

Charlas de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 may 2026, 19:18 UTC

Ganancias

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 may 2026, 19:16 UTC

Ganancias

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 may 2026, 19:08 UTC

Ganancias

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 may 2026, 19:05 UTC

Ganancias

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 may 2026, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 may 2026, 18:51 UTC

Ganancias

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 may 2026, 18:49 UTC

Ganancias

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 may 2026, 18:41 UTC

Ganancias

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 may 2026, 17:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 may 2026, 17:14 UTC

Ganancias

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 may 2026, 17:04 UTC

Charlas de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 may 2026, 15:39 UTC

Charlas de Mercado

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 may 2026, 15:39 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 may 2026, 15:39 UTC

Charlas de Mercado

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 may 2026, 15:36 UTC

Charlas de Mercado

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 may 2026, 15:20 UTC

Charlas de Mercado

'Altcoin Season' Indicator on the Rise -- Market Talk

8 may 2026, 15:20 UTC

Charlas de Mercado

Ganancias

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 may 2026, 15:05 UTC

Charlas de Mercado

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 may 2026, 14:42 UTC

Charlas de Mercado

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 may 2026, 14:39 UTC

Charlas de Mercado

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

41.97% repunte

Estimación a 12 Meses

Media 136.62 USD 41.97%

Máximo 158 USD

Mínimo 105 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentimiento

By Acuity

1 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.